Estrogen receptor degradation: a CUE for endocrine resistance?
Despite the undoubted success of adjuvant endocrine therapies that target the estrogen receptor pathway, not all women with estrogen receptor-positive breast cancer respond to these therapies, and many who initially respond will subsequently relapse. Deregulation of various aspects of estrogen receptor signaling has been highlighted as a mechanism of resistance and as a basis for alternative therapeutic approaches. However, a recent publication refocuses attention on the estrogen receptor itself by showing that the ubiquitin-binding CUE domain-containing protein 2 is a regulator of estrogen receptor protein degradation and a marker of endocrine resistance in breast cancer.
|Publisher Name||BREAST CANCER RES|
|Published Date||2011-09-01 00:00:00|
|OpenAccess Link||https://publications.gimr.garvan.org.au/download.php?11101_11571/11 Musgrove bcr2914.pdf|